# Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (A

Source: https://onco.cc/trials/nct04846634/  
OnCo record `nct04846634` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of penpulimab, cisplatin, carboplatin, pemetrexed and other drugs in lung cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.

## Summary

Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043) is a phase 2, randomised interventional study registered as NCT04846634 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 90 participants, started 2021-08 and due to reach its primary completion in 2023-03. Interventions recorded: Penpulimab+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel; Penpulimab+Anlotinib+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel; Penpulimab+Anlotinib. Conditions listed: Resectable Locally Advanced Non-small Cell Lung Cancer. Primary outcome: Major pathological response (MPR). Lung eligibility wording from the registry: "* Early stage IIB-IIIB (N2), operable non-small cell lung cancer, confirmed in tissue". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Also known as: ALTER-L043
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT04846634
- Phase: 2
- Setting: Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)
- Sponsor: Tianjin Medical University Cancer Institute and Hospital
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT04846634: https://clinicaltrials.gov/study/NCT04846634

## Connected records

- cancers: [Unresectable stage III non-small-cell lung cancer](https://onco.cc/cancers/stage-iii-unresectable-nsclc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Anlotinib](https://onco.cc/drugs/anlotinib/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/), [Penpulimab](https://onco.cc/drugs/penpulimab/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04846634.json